Oncological and Survival Endpoints in Cancer Cachexia Clinical Trials: Systematic Review 6 of the Cachexia Endpoints Series
Journal of Cachexia, Sarcopenia and Muscle · 2025-04 · 16 (2)
DOI: 10.1002/jcsm.13756 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 10.03.2025. Verfasst von Olav Dajani und 23 weiteren Autor:innen. Beteiligte Einrichtung: Regional Advisory Unit for Palliative Care, Dept. of Oncology, Oslo University Hospital/European Palliative Care Research Centre (PRC), Dept. of Onco…. Hauptthemen laut MEDLINE: Cachexia, Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
In patients receiving anti‐cancer treatment, cachexia results in poorer oncological outcomes. However, there is limited understanding and no systematic review of oncological endpoints in cancer cachexia (CC) trials. This review examines oncological endpoints in CC clinical trials.
Methods
An electronic literature search of MEDLINE, Embase and Cochrane databases (1990–2023) was performed. Eligibility criteria comprised participants ≥ 18 years old; controlled design; ≥ 40 participants; and a cachexia intervention for > 14 days. Trials reporting at least one oncological endpoint were selected for analysis. Data extraction was performed using Covidence and followed PRISMA guidelines and the review was registered (PROSPERO CRD42022276710).
Results
Fifty‐seven trials were eligible, totalling 9743 patients (median: 107, IQR: 173). Twenty‐six (46%) trials focussed on a single tumour site: eight in lung, six in pancreatic, six in head and neck and six in GI cancers. Forty‐two (74%) studies included patients with Stage III/IV disease, and 41 (70%) included patients receiving palliative anti‐cancer treatment. Ten studies (18%) involved patients on curative treatment. Twenty‐eight (49%) studies used pharmacological interventions, 29 (50%) used oral nutrition, and two (4%) used enteral or parenteral nutrition. Reported oncological endpoints included overall survival (OS, n = 46 trials), progression‐free survival (PFS, n = 7), duration of response (DR, n = 1), response rate (RR, n = 9), completion of treatment (TC, n = 11) and toxicity/adverse events (AE, n = 42). Median OS differed widely from 60 to 3468 days. Of the 46 studies, only three reported a significant positive effect on survival. Seven trials showed a difference in AE, four in TC, one in PFS and one in RR. Reported significances were unreliable due to missing adjustments for extensive multiple testing. Only three of the six trials using OS as the primary endpoint reported pre‐trial sample size calculations, but only one recruited the planned number of patients.
Conclusion
In CC trials, oncological endpoints were mostly secondary and only few significant findings have been reported. Due to heterogeneity in oncological settings, nutritional and metabolic status and interventions, firm conclusions about CC treatment are not possible. OS and AE are relevant endpoints, but future trials targeting clinically meaningful hazard ratios will required more homogeneous patient cohorts, adequate pre‐trial power analyses and adherence to statistical testing standards.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Regional Advisory Unit for Palliative Care, Dept. of Oncology, Oslo University Hospital/European Palliative Care Research Centre (PRC), Dept. of Oncology, Oslo University Hospital, and Institute of Clinical Medicine, Un…
- Edinburgh Cancer Research Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
- Department of Clinical Medicine, Clinical Nutrition Research Group, UiT The Arctic University of Norway, Tromsø, Norway.
- Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU - Norwegian University of Science and Technology, Trondheim, Norway.
- Royal Infirmary of Edinburgh, Clinical Surgery University of Edinburgh, Edinburgh, UK.
- Department of Nursing and Health Promotion, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.
ORCID-Profile: Michael S Yule, Jann Arends
Zitieren
APA
Dajani, O., Philips, I., Størkson, E. K., Balstad, T. R., Brown, L. R., Bye, A., Dolan, R., Greil, C., Hjermstad, M., Jakobsen, G., Kaasa, S., McDonald, J., Ottestad, I., Sayers, J., Simpson, M., Sousa, M. S., Vagnildhaug, O. M., Yule, M. S., Laird, B. J. A., …, & Cancer Cachexia Endpoints Working Group (2025). Oncological and Survival Endpoints in Cancer Cachexia Clinical Trials: Systematic Review 6 of the Cachexia Endpoints Series. Journal of Cachexia, Sarcopenia and Muscle, 16(2). https://doi.org/10.1002/jcsm.13756
Vancouver
Dajani O, Philips I, Størkson EK, Balstad TR, Brown LR, Bye A, et al. Oncological and Survival Endpoints in Cancer Cachexia Clinical Trials: Systematic Review 6 of the Cachexia Endpoints Series. Journal of Cachexia, Sarcopenia and Muscle. 2025;16(2). doi:10.1002/jcsm.13756
BibTeX
@article{Dajani2025,
author = {Dajani, Olav and Philips, Iain and Størkson, Ester Kristine and Balstad, Trude R and Brown, Leo R and Bye, Asta and Dolan, Ross and Greil, Christine and Hjermstad, Marianne and Jakobsen, Gunnhild and Kaasa, Stein and McDonald, James and Ottestad, Inger and Sayers, Judith and Simpson, Melanie and Sousa, Mariana S and Vagnildhaug, Ola Magne and Yule, Michael S and Laird, Barry J A and Skipworth, Richard J E and Solheim, Tora S and Stares, Mark and Arends, Jann and Cancer Cachexia Endpoints Working Group, Cancer Cachexia Endpoints Working Group},
title = {Oncological and Survival Endpoints in Cancer Cachexia Clinical Trials: Systematic Review 6 of the Cachexia Endpoints Series},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2025},
volume = {16},
number = {2},
doi = {10.1002/jcsm.13756}
}
EUVIMED